Q1 2025 Earnings Forecast for Eli Lilly and Company Issued By Zacks Research (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) – Equities research analysts at Zacks Research lowered their Q1 2025 earnings estimates for shares of Eli Lilly and Company in a report issued on Wednesday, April 17th. Zacks Research analyst K. Shah now anticipates that the company will earn $4.77 per share for the quarter, down from their previous estimate of $4.80. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $12.52 per share. Zacks Research also issued estimates for Eli Lilly and Company’s Q2 2025 earnings at $4.07 EPS, Q3 2025 earnings at $4.46 EPS, Q4 2025 earnings at $4.50 EPS and FY2025 earnings at $17.80 EPS.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.09 EPS.

LLY has been the topic of several other reports. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $815.00 price target on shares of Eli Lilly and Company in a research note on Monday. The Goldman Sachs Group increased their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. BMO Capital Markets increased their price target on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Finally, Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Stock Down 0.6 %

LLY opened at $745.95 on Thursday. The firm has a 50-day simple moving average of $764.24 and a two-hundred day simple moving average of $658.28. Eli Lilly and Company has a 52 week low of $367.35 and a 52 week high of $800.78. The company has a market capitalization of $708.77 billion, a PE ratio of 128.61, a price-to-earnings-growth ratio of 1.63 and a beta of 0.34. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of the business’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the transaction, the insider now directly owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Eli Lilly and Company

A number of large investors have recently made changes to their positions in LLY. Simon Quick Advisors LLC raised its stake in Eli Lilly and Company by 10.5% in the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after acquiring an additional 278 shares during the last quarter. Clear Harbor Asset Management LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $363,000. WASHINGTON TRUST Co boosted its position in Eli Lilly and Company by 16.5% in the fourth quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock valued at $11,013,000 after buying an additional 2,671 shares during the last quarter. Liontrust Investment Partners LLP acquired a new position in Eli Lilly and Company in the 3rd quarter worth approximately $8,326,000. Finally, Redhawk Wealth Advisors Inc. raised its position in Eli Lilly and Company by 0.9% during the 3rd quarter. Redhawk Wealth Advisors Inc. now owns 6,986 shares of the company’s stock worth $3,752,000 after buying an additional 65 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.